



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/125969/>

Version: Accepted Version

---

**Article:**

Elf, S, Abdelfattah, NS, Baral, AJ et al. (2018) Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. *Blood*, 131 (7). pp. 782-786.

ISSN: 0006-4971

<https://doi.org/10.1182/blood-2017-08-800896>

---

(c) 2017, American Society of Hematology. This research was originally published in *Blood Online*, 'Elf, S, Abdelfattah, NS, Baral, AJ et al (2017). Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. *Blood*.' Published December 29, 2017. DOI: <https://doi.org/10.1182/blood-2017-08-800896>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

## **Defining the requirements for the pathogenic interaction between mutant calreticulin and the thrombopoietin receptor in MPN**

Shannon Elf<sup>1,6</sup>, Nouran S. Abdelfattah<sup>1,6</sup>, April J. Baral<sup>2,6</sup>, Danielle Beeson<sup>1</sup>, Jeanne F. Rivera<sup>2</sup>, Amy Ko<sup>3</sup>, Natalie Florescu<sup>1</sup>, Gabriel Birrane<sup>4,5</sup>, Edwin Chen<sup>2,7</sup>, and Ann Mullally<sup>1,3,6,7</sup>

### **Correspondence:**

Ann Mullally, MD [amullally@partners.org](mailto:amullally@partners.org)  
Phone: (617) 525-4955 Fax: (617) 525-4986

Harvard Institutes of Medicine Building, Room 738 77 Avenue Louis Pasteur Boston, MA 02115

OR

Edwin Chen, PhD [e.chen@leeds.ac.uk](mailto:e.chen@leeds.ac.uk) phone: 0044 0113 34 33162

School of Molecular and Cellular Biology  
Faculty of Biological Sciences  
University of Leeds  
Woodhouse Lane  
Leeds LS2 9JT  
United Kingdom

### **Key Points**

- The binding of mutant calreticulin to MPL can be uncoupled from MPL activation.
- The lectin activity but not the chaperone functionality of CALR<sup>MUT</sup> is required for cytokine independent growth.

---

<sup>1</sup> School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom

<sup>2</sup> Broad Institute, Cambridge, Massachusetts 02142, USA.

<sup>3</sup> Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

<sup>4</sup> Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

<sup>5</sup> These authors contributed equally to this work.

<sup>6</sup> Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

<sup>7</sup> These authors contributed equally to this work.

## **Abstract**

Mutations in calreticulin (*CALR*) are phenotypic drivers in the pathogenesis of myeloproliferative neoplasms (MPN). Mechanistic studies have demonstrated that mutant *CALR* binds to the thrombopoietin receptor *MPL*, and that the positive electrostatic charge of the mutant *CALR* C-terminus is required for mutant *CALR*- mediated activation of JAK-STAT signaling. Here we demonstrate that although binding between mutant *CALR* and *MPL* is required for mutant *CALR* to transform hematopoietic cells, binding alone is insufficient for cytokine independent growth. We further show that the threshold of positive charge in the mutant *CALR* C-terminus influences both binding of mutant *CALR* to *MPL* and activation of *MPL* signaling. We find that mutant *CALR* binds to the extra-cellular domain of *MPL* and that three tyrosine residues within the intracellular domain of *MPL* are required to activate signaling. With respect to mutant *CALR* function, we show that its lectin-dependent function is required for binding to *MPL* and for cytokine independent growth while its chaperone and polypeptide binding functionalities are dispensable. Together, our findings provide additional insights into the mechanism of the pathogenic mutant *CALR*-*MPL* interaction in MPN.

## Introduction

Recurrent mutations in calreticulin (*CALR*), an endoplasmic reticulum (ER) resident chaperone protein, represent the second most common mutation in patients with myeloproliferative neoplasms (MPN) after *JAK2V617F* (1-4). *CALR* mutations in MPN occur as a heterogeneous set of indel mutations in exon 9 of *CALR* that all result in a +1 base pair frameshift in the *CALR* reading frame (5, 6). Although the mutant *CALR* C-terminal alterations vary, all *CALR* mutations lead to loss of most of the C-terminal acidic domain and concomitant gain of a novel C-terminus consisting of 36 amino acids which are enriched for positively charged residues. Mechanistic studies have demonstrated that mutant *CALR* (*CALR*<sup>MUT</sup>) binds to the thrombopoietin receptor, MPL to activate the MPL-JAK-STAT signaling axis (7-10), and that the positive charge of the *CALR*<sup>MUT</sup> C-terminus is required to mediate this interaction (9).

Several unanswered questions remain regarding the molecular and functional basis of *CALR*<sup>MUT</sup> oncogenic activity. In this report, we use a series of mutagenesis experiments to address some of these questions, focusing on the structural determinants of *CALR*<sup>MUT</sup> and MPL that are necessary for hematopoietic cell transformation.

## Materials and Methods

*Ba/F3 Cell Growth Assays.* Ba/F3 cells expressing *CALR*<sup>MUT</sup> or MPL variants were generated by retroviral transduction and assayed for cytokine-independent growth as previously described (9).

*In Vitro Binding Assay.* V5-tagged purified recombinant *CALR*<sup>WT</sup>, *CALR*<sup>MUT</sup>, *CALR*<sup>MUT</sup>-D135L and *CALR*<sup>MUT</sup>-D317A proteins were incubated with purified recombinant ERp57 or MPL for 30 minutes at 4°C, and washed with HEPES-acetate buffer. Bound proteins were eluted from

beads and analyzed by SDS-PAGE.

## Results and Discussion

To resolve which amino acids within the CALR<sup>MUT</sup> C-terminus are required for CALR<sup>MUT</sup> activity, we generated CALR<sup>MUT</sup> variants harboring serial truncations of the mutant C-terminal tail in blocks of 8-10 amino acids (**Figure 1A**) and tested their ability to associate with MPL in pull-down assays. All CALR<sup>MUT</sup> variants examined retained the ability to bind MPL (**Figure 1B**). However, the most severely truncated form (CALR<sup>MUT</sup>A36) failed to activate JAK-STAT signaling (**Figure 1C**), stimulate phosphorylation of MPL (**Figure 1D**), and transform Ba/F3-MPL cells to IL-3 independence (**Figure 1E**). Further truncation of an 11 amino acid positively charged stretch (QRTRRMMRTKM) that is also present in CALR<sup>MUT</sup> protein species generated by the 52 bp deletion (CALR<sup>MUT</sup>A47, **Supplemental Figure S1A**) led to loss of MPL binding (**Supplemental Figure S1B**) and inability to transform Ba/F3-MPL cells (**Supplemental Figure S1C**). A CALR<sup>MUT</sup> variant where these 11 residues are deleted but the distal 36 mutant-specific amino acids are retained (CALR<sup>MUT</sup>A37-47) was still able to bind to MPL and transform Ba/F3-MPL cells (**Supplemental Figure S1A-C**), suggesting that the QRTRRMMRTKM stretch is sufficient but not strictly required for MPL binding. Our data also suggest that whilst CALR<sup>MUT</sup>A36 can bind to MPL, this binding is insufficient to activate MPL signaling. To our knowledge, these data provide the first evidence that physical interaction between CALR<sup>MUT</sup> and MPL is not *ipso facto* sufficient to activate MPL. Rather, our data argue for a model whereby different thresholds of positive charge in the CALR<sup>MUT</sup> C-terminus are required to enable binding of CALR<sup>MUT</sup> to MPL and to activate MPL signaling. As MPL phosphorylation is dependent on homodimerization of single MPL chains, these data may suggest that CALR<sup>MUT</sup>A36 retains the ability to interact with single MPL chains but is unable to induce homodimerization which is required for receptor activation. Further studies are

warranted to fully resolve the three-dimensional structure of the CALR<sup>MUT</sup>-MPL interaction.

We next sought to elucidate the regions of MPL that are essential to support CALR<sup>MUT</sup> activity. We observed that CALR<sup>MUT</sup> binds to full length MPL and to the extracellular and transmembrane (EC+TM) fragment of MPL, but not to the intracellular and transmembrane (IC+TM) fragment (**Figure 1F**). Furthermore, a MPL variant where the thrombopoietin (TPO) binding site is mutated (D235A/L239A) (11) was still able to bind to CALR<sup>MUT</sup> (**Supplemental Figure S1D**) and could support CALR<sup>MUT</sup>-mediated cytokine-independent growth in Ba/F3 cells (**Supplemental Figure S1E**). This suggests that CALR<sup>MUT</sup> does not occupy the same binding pocket as TPO and is consistent with CALR<sup>MUT</sup>-driven hematopoietic transformation being a TPO-independent process (7).

Analysis of the intracellular portion of MPL reveals three tyrosine residues (Y591, Y626 and Y631) which may also be important for CALR<sup>MUT</sup>-MPL signaling (12). MPL variants were therefore generated where these residues were systematically mutated to phenylalanine individually (FYY, YFY, YYF), in tandem (FFY, FYF, YFF) or altogether (FFF). As expected, all MPL variants were able to physically interact with CALR<sup>MUT</sup> in FLAG-pull down assays (**Figure 1G**). However, we found differences in their ability to support CALR<sup>MUT</sup> signaling. MPL variants harboring intact Y626 (MPL-FYY, MPL-YYF, MPL-FYF) supported robust Stat5 phosphorylation (**Figure 1H**) in association with cytokine-independent growth (**Figure 1I**), but not MPL variants in which the Y626 is mutated (MPL-YFY, MPL-YFF, MPL-FFY, MPL-FFF). These data indicate that Y626 plays a more prominent role than Y591 and Y631 in MPL signaling downstream of CALR<sup>MUT</sup>, which is consistent with a previous report identifying Y626 as the major signaling tyrosine in canonical TPO-MPL signaling (12). Our data therefore highlight the importance of tyrosine-mediated MPL signaling as a pathway co-opted by

CALR<sup>MUT</sup> to effect cytokine-independent proliferation. Our studies do not rule out a role for nontyrosine residues of MPL, which may be required for CALR<sup>MUT</sup>-mediated activation of other downstream signaling pathways (e.g. ERK) (13) and future studies to explore this question are warranted.

Finally, we sought to gain functional insights into how CALR<sup>MUT</sup> interacts with MPL to confer cytokine independent growth. Wild-type calreticulin is an ER-resident chaperone that interacts with glycoproteins by binding to Glc1Man9GlcNAc2 oligosaccharides and the polypeptide backbone to facilitate proper protein folding. We therefore created variants of CALR<sup>MUT</sup> harboring mutations in critical residues implicated in three key functionalities of wild-type CALR - (i) polypeptide binding, (ii) chaperone activity, and (iii) lectin activity - and tested their capacity to bind to MPL and confer cytokine- independence (**Figure 2A**).

We observed that both polypeptide binding-deficient variants of CALR<sup>MUT</sup> (CALR<sup>MUT</sup>-P19K/V21E and CALR<sup>MUT</sup>-W244G) and chaperone-deficient variants of CALR<sup>MUT</sup> (CALR<sup>MUT</sup>-H153G and CALR<sup>MUT</sup>-EEDE) (14-15) retained MPL binding ability (**Figure 2B**) and conferred cytokine-independent growth (**Figure 2C**). Consistent with the nonessentiality of chaperone functionality in CALR<sup>MUT</sup> oncogenic activity, CALR<sup>WT</sup> exhibits strong, direct binding to the ERp57 co-chaperone, whereas CALR<sup>MUT</sup> does not (**Figure 2D**). In contrast, lectin-deficient CALR<sup>MUT</sup> variants harboring mutations in Asp-135 and Asp-317 (CALR<sup>MUT</sup>-D135L and CALR<sup>MUT</sup>-D317A) (16-17) were both unable to bind to MPL or confer cytokine independence (**Figure 2B-C**). In accordance, we also found that only recombinant CALR<sup>MUT</sup> protein directly binds to recombinant MPL in an *in vitro* binding assay, whereas neither CALR<sup>WT</sup> nor lectin-deficient CALR<sup>MUT</sup> bind (**Figure 2E**). These data explain the previously reported essential role for Asp-135 in mediating CALR<sup>MUT</sup>-driven STAT5 activation (8) as being due to a requirement

for Asp-135 in mediating binding between CALR<sup>MUT</sup> to MPL. Finally, to determine the requisite glycosylation status of MPL that enables CALR<sup>MUT</sup> binding, we tested CALR<sup>MUT</sup> binding to MPL mutants where either two (2xNQ = N117/178Q) or all four (4xNQ = N117/178/298/358Q) glycosylation sites in the extra-cellular domain of MPL were abolished. We found that CALR<sup>MUT</sup> can still bind to MPL-2xNQ but not to MPL-4xNQ (*Figure 2F*). These data are consistent with a previous report which demonstrated that MPL variants devoid of the same four N-glycosylation sites failed to support STAT5 activation by CALR<sup>MUT</sup> (8), and suggests that this defect is due to an inability of unglycosylated MPL to bind CALR<sup>MUT</sup>.

In conclusion, our data provide additional insights into the molecular mechanism by which CALR<sup>MUT</sup> interacts with MPL to induce MPN (**Supplemental Table 1**). Specifically, we (i) uncouple the binding of CALR<sup>MUT</sup> to MPL from MPL activation, (ii) define the key properties of MPL required for CALR<sup>MUT</sup> binding and for its activation and (iii) decipher the key functionalities of CALR<sup>MUT</sup> required for its oncogenic activity.

**Acknowledgements:** This work was supported by the NIH (R01HL131835 to AM), a Damon Runyon clinical investigator award (AM), the Starr Cancer Consortium (AM), the Leukemia and Lymphoma Society (LLS) (AM), the Wellcome Trust (EC), an Academy of Medical Science Springboard Award (EC), a Leuka John Goldman Fellowship (EC), and the Gabrielle's Angel Foundation for Cancer Research (GB). SE is a recipient of a T32 molecular hematology training award (NHLBI) and an LLS Special Fellow Award.

**Authorship Contributions:** SE, NSA, EC, and AM designed the study, while GB provided guidance on experimental design. SE, NSA, AJB, DB, GB, JFR, AK, and NF, performed experiments and collected the data, SE, NSA, AJB and DB analyzed the data. SE, NSA, EC, and AM wrote the manuscript.

**Disclosure of Conflicts of Interest:** The authors have no conflict of interest to declare.

## References

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet (London, England)*. 2005;365(9464):1054-61. Epub 2005/03/23. doi: 10.1016/s0140-6736(05)71142-9. PubMed PMID: 15781101.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*.7(4):387-97. doi: 10.1016/j.ccr.2005.03.023.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-8. Epub 2005/03/29. doi: 10.1038/nature03546. PubMed PMID: 15793561.
4. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. *New England Journal of Medicine*. 2005;352(17):1779-90. doi: doi:10.1056/NEJMoa051113. PubMed PMID: 15858187.
5. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanese C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379-90. doi: 10.1056/NEJMoa1311347. PubMed PMID: 24325356.
6. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du M-Q, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. *New England Journal of Medicine*. 2013;369(25):2391-405. doi: doi:10.1056/NEJMoa1312542. PubMed PMID: 24325359.
7. Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. *Blood*. 2016;127. doi: 10.1182/blood-2015-11-679571.
8. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. *Blood*. 2016;127. doi: 10.1182/blood-2015-11-681932.
9. Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. *Cancer Discov*. 2016;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. PubMed PMID: 26951227; PMCID: PMC4851866.
10. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S,

Shirane S, Eda Hiro Y, Sunami Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. *Blood*. 2016;127(10):1307-16. Epub 2016/01/29. doi: 10.1182/blood-201509-671172. PubMed PMID: 26817954.

11. Chen WM, Yu B, Zhang Q, Xu P. Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC). *The Journal of biological chemistry*. 2010;285(34):26697-709. Epub 2010/06/10. doi: 10.1074/jbc.M110.120956. PubMed PMID: 20529857; PMCID: PMC2924112.

12. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. *Proc Natl Acad Sci U S A*. 1997 Mar 18;94(6):2350-5. PubMed PMID: 9122198; PMCID: PMC20091.

13. Han L, Schubert C, Kohler J, Schemionek M, Isfort S, Brummendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. *J Hematol Oncol*. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0. PubMed PMID: 27177927 PMCID: PMC4894373

14. Kapoor M, Ellgaard L, Gopalakrishnapai J, Schirra C, Gemma E, Oscarson S, Helenius A, Surolija A. Mutational analysis provides molecular insight into the carbohydrate-binding region of calreticulin: pivotal roles of tyrosine-109 and aspartate-135 in carbohydrate recognition. *Biochemistry*. 2004 Jan 13;43(1):97-106. PubMed PMID: 14705935 doi: 10.1021/bi0355286

15. Thomson SP, Williams DB. Delineation of the lectin site of the molecular chaperone calreticulin. *Cell Stress Chaperones*. 2005 Autumn;10(3):242-51. PubMed PMID: 16184769 PMCID: PMC1226022

16. Guo L, Groenendyk J, Papp S, Dabrowska M, Knoblauch B, Kay C, Parker JM, Opas M, Michalak M. Identification of an N-domain histidine essential for chaperone function in calreticulin. *J Biol Chem*. 2003 Dec 12;278(50):50645-53. Epub 2003 Oct 1. doi:10.1074/jbc.M309497200. PubMed PMID: 14522955.

17. Martin V, Groenendyk J, Steiner SS, Guo L, Dabrowska M, Parker JM, Muller-Esterl W, Opas M, Michalak M. Identification by mutational analysis of amino acid residues essential in the chaperone function of calreticulin. *J Biol Chem*. 2006 Jan 27;281(4):2338-46. Epub 2005 Nov 16. DOI: 10.1074/jbc.M508302200. PubMed PMID: 16291754

### Figure Legends

**Figure 1. Binding of mutant calreticulin to MPL is required to transform hematopoietic cells but binding alone is insufficient for cytokine independent growth** (A) Schema depicting serial C-terminal truncation mutants of mutant CALR. (B) Immunoblotting of FLAG immunoprecipitated proteins and whole cell lysates from 293T cells co-transfected with FLAG-CALR wild type (CALR<sup>WT</sup>), FLAG-CALR 52 bp deletion (CALR<sup>mut</sup>), or FLAG-CALR 52 bp deletion serial C-terminal truncation mutants (CALR<sup>MUT</sup> A10-A36) demonstrates that mutant CALR truncated up to A36 still binds to MPL. (C) Immunoblotting demonstrates phosphorylation of Stat5 and Stat3 in Ba/F3-MPL cells expressing CALR<sup>MUT</sup> and truncation

variants A10, A18, and A28, but not A36. (D) Immunoblotting demonstrates phosphorylation of MPL in Ba/F3-MPL cells expressing CALR<sup>MUT</sup> and A28, but not A36. (E) Growth curves in Ba/F3-MPL cells expressing CALR<sup>wt</sup>, CALR<sup>mut</sup>, or CALR<sup>MUT</sup> C-terminal truncation variants demonstrates that only severe truncation of the mutant CALR C-terminus (A36) abolishes the transforming capacity of mutant CALR. (F) Immunoblotting of FLAG immunoprecipitated proteins from 293T cells co-transfected with FLAG-CALR 52 bp deletion (CALR<sup>MUT</sup>) and GST-tagged full length MPL, GST-tagged MPL intracellular + transmembrane domains (IC+TM), or GST-tagged MPL extracellular + transmembrane domains (EC+TM) demonstrates that mutant CALR binds to the extracellular domain of MPL. (G) Immunoblotting of FLAG immunoprecipitated proteins from 293T cells co-expressing FLAG-tagged mutant CALR and MPL YF variants demonstrates that mutations of intracellular tyrosine residues on MPL does not affect the ability of mutant CALR to bind to MPL. (H) Immunoblotting demonstrates that phosphorylation of Stat5 is abrogated in Ba/F3 cells expressing MPL YF variants harboring loss of Y626. (I) Growth curves in Ba/F3 cells stably expressing MPL-YF variants demonstrates that all three intracellular tyrosines play a role in supporting cytokine independent growth in Ba/F3 cells mediated by mutant CALR.

**Figure 2. The lectin-dependent function of mutant CALR is required for cytokine independent growth while its chaperone and polypeptide binding functionalities are dispensable** (A) Schema depicting mutations introduced into the lectin (dark red), polypeptide binding (blue), and chaperone (light green) domains of mutant CALR. (B) Immunoblotting of FLAG immunoprecipitated proteins from 293T cells co-transfected with wild type CALR, mutant CALR, or mutant CALR lectin-, chaperone- and polypeptide binding-deficient variants demonstrates that binding between mutant CALR and MPL is lost when residues required for lectin binding are mutated but binding is retained when residues critical for CALR chaperone and polypeptide binding functionality are mutated. (C) Growth curves in

Ba/F3-MPL cells expressing wild type CALR, mutant CALR, or mutant CALR lectin- (*left*), chaperone- (*middle*) and polypeptide binding-deficient (*right*) variants demonstrates that mutant CALR loses its ability to drive cytokine independent growth when residues required for lectin binding are mutated but retains its ability to drive cytokine independent growth in when residues critical for CALR chaperone and polypeptide binding functionality are mutated. (D) *In vitro* binding assay between purified recombinant CALR<sup>WT</sup> or CALR<sup>MUT</sup> and purified recombinant ERp57 demonstrates that CALR<sup>WT</sup> binds directly to ERp57 but CALR<sup>MUT</sup> does not. (E) *In vitro* binding assay between purified recombinant CALR<sup>WT</sup>, CALR<sup>MUT</sup>, CALR<sup>MUT</sup>-D135L or CALR<sup>MUT</sup>-D317A demonstrates that CALR<sup>MUT</sup> binds directly to MPL but not CALR<sup>WT</sup> or altered CALR<sup>MUT</sup> variants. (F) FLAG pulldown in 293T cells co-expressing CALR<sup>MUT</sup> and MPL glycosylation mutants (2xNQ = N117/178Q; 4xNQ = N117/178/298/358Q), shows CALR<sup>MUT</sup> binding to MPL-2xNQ but not to MPL-4xNQ.




Figure 1









Figure 2